Androgen receptor CpG island methylation status in human leukemia cancer cells

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 156-162

  Liu, Ze Jun ^a   Wang, Gang ^a   Cai, Yun ^a   Gu, Shou Zhi ^b   Zhang, Xiao Bing ^a   Liu, Li ^a   Gao, Xing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SEIREI CHRISTOPHER UNIVERSITY   (Japan)

Author keywords

Androgen receptor; DNA methylation; Leukemia; MSP

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; DNA; MESSENGER RNA;

ADOLESCENT; ADULT; ANDROGEN RECEPTOR GENE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALE; METHYLATION; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ADULT; AZACITIDINE; CELL LINE, TUMOR; CHILD; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 60849121971     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802208590     Document Type: Article

References (54)

1. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240(4854), 889-894.
2. Eliassen, A.H.; Missmer, S.A.; Tworoger, S.S.; Spiegelman, D.; Barbieri, R.L.; Dowsett, M.; Hankinson, S.E. Endogenous steroid hormone concentrations and risk of breast cancer among pre-menopausal women. J Natl Cancer Inst 2006, 98(19), 1406-1415.
3. Campan, M.; Weisenberger, D.J.; Laird, P.W. DNA methylation profiles of female steroid hormone-driven human malignancies. Curr Top Microbiol Immunol. 2006, 310, 141-178.
4. Uchikawa, J.; Shiozawa, T.; Shih, H.C.; Miyamoto, T.; Feng, Y.Z.; Kashima, H.; Oka, K.; Konishi, I. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 2003, 98(10), 2207-2213.
5. Rau, K.M.; Kang, H.Y.; Cha, T.L.; Miller, S.A.; Hung, M.C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005, 12(3), 511-532.
6. Melki, J.R.; Clark, S.J. DNA methylation changes in leukaemia. Semin Cancer Biol 2002, 12(5), 347-357.
7. Melki, J.R.; Vincent, P.C; Clark, S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999, 59(15), 3730-3740.
8. Rush, L.J.; Raval, A.; Funchain, P.; Johnson, A.J.; Smith, L.; Lucas, D.M.; Bembea, M.; Liu, T.H.; Heerema, N.A.; Rassenti, L.; Liyanarachchi, S.; Davuluri, R. et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004, 64(7), 2424-2433.
9. Rush, L.J.; Plass, C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett 2002, 185(1), 1-12.
10. Cross, S.H.; Bird, A.P. CpG islands and genes. Curr Opin Genet Dev 1995, 5(3), 309-314.
11. Bird, A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067), 209-213.
12. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J Mol Biol 1987, 196(2), 261-282.
13. Moriguchi, K.; Yamashita, S.; Tsujino, Y.; Tatematsu, M.; Ushijima, T. Larger numbers of silenced genes in cancer cell lines with increased de novo methylation of scattered CpG sites. Cancer Lett 2007, 249(2), 178-187.
14. Baylin, S.B.; Chen, W.Y. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 2005. 70, 427-433.
15. Czekierdowski, A.; Czekierdowska, S.; Wielgos, M.; Smolen, A.; Kaminski, P.; Kotarski, J. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 2006, 27(3), 381-386.
16. Gebhard, C.; Schwarzfischer, L.; Pham, T.H.; Schilling, E.; Klug, M.; Andreesen, R.; Rehli, M. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 2006, 66(12), 6118-6128.
17. Jair, K.W.; Bachman, K.E.; Suzuki, H.; Ting, A.H.; Rhee, I.; Yen, R.W.; Baylin, S.B.; Schuebel, K.E. De novo CpG island methylation in human cancer cells. Cancer Res 2006, 66(2), 682-692.
18. Agirre, X.; Roman-Gomez, J.; Vazquez, I.; Jimenez-Velasco, A.; Garate, L.; Montiel-Duarte, C.; Artieda, P.; Cordeu, L.; Lahortiga, I.; Calasanz, M.J.; Heiniger, A.; Torres, A. et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronicmyeloid leukemia. Int J Cancer 2006, 118(8), 1945-1953.
19. Liu, Z.J.; Lu, X.; Zhang, Y.; Zhong, S.; Gu, S.Z.; Zhang, X.B.; Yang, X.; Xin, H.M. Downregulated mRNA expression of ASPP and the hypermethylation of the 5′-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett 2005, 579(7), 1587-1590.
20. Issa, J.P.; Baylin, S.B.; Herman, J.G. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997, 11(Suppl 1), S7-11.
21. Issa, J.P.; Zehnbauer, B.A.; Civin, C.I.; Collector, M.I.; Sharkis, S.J.; Davidson, N.E.; Kaufmann, S.H.; Baylin, S.B. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 1996, 56(5), 973-977.
22. Liu ,Z.J.; Zhang, X.B.; Zhang, Y.; Yang, X. Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett 2004, 567(2-3), 327-332.
23. Lubahn, D.B.; Joseph, D,R,; Sullivan, P.M.; Willard, H.F.; French, F.S.; Wilson, E.M. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988, 240(4850), 327-330.
24. Kuiper, G.G.; Faber, P.W.; van Rooij, H.C.; van der Korput, J.A.; Ris-Stalpers, C.; Klaassen, P.; Trapman, J.; Brinkmann, A.O. Structural organization of the human androgen receptor gene. J Mol Endocrinol 1989, 2(3), R1-4.
25. Felgner, J.; Heidorn, K.; Korbacher, D.; Frahm, S.O.; Parwaresch, R. Cell lineage specificity in G-CSF receptor gene methylation. Leukemia 1999, 13(4), 530-534.
26. MethPrimer. Available from : http://www.urogene.org/methprimer/index1. html.
27. Li, L.C.; Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11), 1427-1431.
28. Gelmann, E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002, 20(13), 3001-3015.
29. Huang, H.; Tindall, D.J. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr 2002, 12(3), 193-207.
30. Chlenski, A.; Nakashiro, K.; Ketels, K.V.; Korovaitseva, G.I.; Oyasu, R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001, 47(1), 66-75.
31. Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G. Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 1998, 58(23), 5310-5314.
32. Sasaki, M.; Tanaka, Y.; Perinchery, G.; Dharia, A.; Kotcherguina, I.; Fujimoto, S.; Dahiya, R. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002, 94(5), 384-390.
33. Sasaki, M.; Oh, B.R.; Dharia, A.; Fujimoto, S.; Dahiya, R. Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer. Mol Carcinog 2000, 29(2), 59-66
34. Shim, H.S.; Jung, W.H.; Kim, H.; Park, K.; Cho, N.H. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS 2006, 114(5), 352-358.
35. Catalano, M.G.; Pfeffer, U.; Raineri, M.; Ferro, P.; Curto, A.; Capuzzi, P.; Corno, F.; Berta, L.; Fortunati, N. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer 2000, 86(3), 325-330.
36. Mantalaris, A.; Panoskaltsis, N.; Sakai, Y.; Bourne, P.; Chang, C.; Messing, E.M.; Wu, J.H. Localization of androgen receptor expression in human bone marrow. J Pathol 2001, 193(3), 361-366.
37. McDonald, H.L.; Gascoyne, R.D.; Horsman, D.; CJ. Involvement of the X chromosome in non-Hodgkin lymphoma. Genes Chromosomes Cancer 2000, 28(3), 246-57.
38. Yang, H.; Chen, C.M.; Yan, P.; Huang, T.H.; Shi, H.; Burger, M.; Nimmrich, I.; Maier, S.; Berlin, K.; Caldwell, C.W. The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. Clin Cancer Res 2003, 9(11), 4034-4042.
39. Jones, P.A.; Takai, D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293(5532), 1068-1070.
40. Jones, P.A. The DNA methylation paradox. Trends Genet 1999, 15(1), 34-37.
41. Nass, S.J.; Herman, J.G.; Gabrielson, E.; Iversen, P.W.; Parl, F.F.; Davidson, N.E.; Graff, J.R. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000, 60(16), 4346-4348.
42. Kang, J.H.; Kim, S.J.; Noh, D.Y.; Park, I.A.; Choe, K.J.; Yoo, O.J.; Kang, H.S. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 2001, 81(4), 573-579.
43. Sharma, G.; Mirza, S.; Prasad, C.P.; Srivastava, A.; Gupta, S.D.; Ralhan, R. Promoter hypermethylation of p16(INK4A), p14(ARF), CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007, 80(20), 1873-1881.
44. Reibenwein, J.; Pils, D.; Horak, P.; Tomicek, B.; Goldner, G.; Worel, N.; Elandt, K.; Krainer, M. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 2007, 67(4), 427-432.
45. Kawakami, K.; Ruszkiewicz, A.; Bennett, G.; Moore, J.; Grieu, F.; Watanabe, G.; Iacopetta, B. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006, 94(4), 593-598.
46. Park, J.; Brena, R.M.; Gruidl, M.; Zhou, J.; Huang, T.; Plass, C.; Tockman, M.S. CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomark 2005, 1(2-3), 193-200.
47. Baylin, S.B.; Herman, J.G.; Graff, J.R.; Vertino, P.M.; Issa, J.P. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998, 72, 141-196.
48. Palmisano, W.A.; Divine, K.K.; Saccomanno, G.; Gilliland, F.D.; Baylin, S.B.; Herman, J.G.; Belinsky, S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000, 60(21), 5954-5958.
49. Liu, Z.J.; Maekawa, M.; Horii, T.; Morita, M. The multiple promoter methylation profile of PR gene and ERalpha gene in tumor cell lines. Life Sci 2003, 73(15), 1963-1972..
50. Yates, D.R.; Rehman, I.; Abbod, M.F.; Meuth, M.; Cross, S.S.; Linkens, D.A.; Hamdy, F.C.; Catto, J.W. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007, 13(7), 2046-2053.
51. Esteller, M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007, 8(4), 286-298.
52. Kastner, P.; Krust, A.; Turcotte, B.; Stropp, U.; Tora, L.; Gronemeyer, H.; Chambon, P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990, 9(5), 1603-1614.
53. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994, 54, (10), 2552-2555.
54. Lapidus, R.G.; Ferguson, A.T.; Ottaviano, Y.L.; Parl, F.F.; Smith, H.S.; Weitzman, S.A.; Baylin, S.B.; Issa, J.P.; Davidson, N.E. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2(5), 805-810.